Get the latest news, insights, and market updates on ACRS (Aclaris Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference
WAYNE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday March 10, 2026, at 1:40 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Leerink Partners 2026 Global Healthcare Conference in Miami, FL. A live a Mar 3, 2026 - $ACRS
Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference
Executives from Aclaris Therapeutics (NASDAQ:ACRS) outlined the company’s clinical-stage pipeline and upcoming catalysts during a presentation at Oppenheimer’s Annual Healthcare Conference, emphasizing programs in inflammatory and immunological diseases spanning monoclonal antibodies, a bispecific a Feb 26, 2026 - $ACRS
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the Second Quarter of 2026 - - Phase 1b Proof-of-Concept Trials of ATI-052 in Atopic Dermatitis (AD) and Asthma Underway; Top Line Results from Both Trials Anticipated in the Second Half of 2026 - - Investigational New Drug (IND) Application for Lead ITK Inhibitor Candidate ATI-9494 Ex Feb 26, 2026 - $ACRS
Aclaris: Q4 Earnings Snapshot
The Wayne, Pennsylvania-based company said it had a loss of 16 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 15 cents per share. Feb 26, 2026 - $ACRS
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +5.39% and +30.48%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock? Feb 25, 2026 - $ACRS
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052
WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1b proof-of-concept (POC) trial of ATI-052, the Company’s potential best-in-class investigational bispecific anti-TSLP/IL-4Rα antibody, in asthma. This announcement follows the recent initiation of the Company’s Phase 1b P Feb 24, 2026 - $ACRS
Aclaris Therapeutics Touts TSLP and ITK Pipeline, Sets Up Multiple Clinical Readouts for 2026
Aclaris Therapeutics (NASDAQ:ACRS) outlined development priorities and upcoming milestones for its biologics and oral small-molecule pipeline during a fireside chat at Guggenheim’s Emerging Outlook Biotech Summit. Company leaders described a two-pronged strategy spanning a TSLP-targeted antibody pla Feb 13, 2026 - $ACRS
February 2026's Promising Penny Stocks To Consider
As February 2026 begins, the U.S. stock market has seen a robust start, with major indexes like the Dow Jones Industrial Average and S&P 500 posting significant gains. This positive momentum reflects broader economic optimism and renewed investor confidence, despite ongoing geopolitical developments and economic policy shifts. In this context, penny stocks—often representing smaller or newer companies—continue to capture interest for their potential to offer growth opportunities at an... Feb 10, 2026 - $ACRS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple